Importantly, RAS/RTK mutations in hyperdiploid tumours were typically clonal, whereas in ERG-deleted ALL mutations were almost exclusively subclonal, suggesting the efficacy of RAS/RTK inhibitors will differ between subtypes. The gene discussed is ERG; the disease is acute lymphoblastic leukemia.